ASSTON PHARMACEUTICALS LIMITED
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

Date: - 30th March, 2026

To,
BSE Limited
Listing / Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Ref: Asston Pharmaceuticlas Limited (ISIN – INE0SJX01015), BSE Code – 544445.

Sub: Outcome of the Board Meeting of the Company and disclosure under Regulation 30 of SEBI (Listing Regulation and Disclosure Requirements) Regulation 2013 held on 30th March, 2026.

Dear Sir / Madam,

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its Meeting held today on 30th March, 2026 at 03:00 P.M. which Concluded at 04:00 P.M. at the registered office of the Company through video conferencing, have considered and approved the following along with other agenda items: -

1. The appointment of Mr. Sumit Pawar as Chief Financial Officer of the Company with effect from 30th March, 2026.
2. The appointment of Mr. Yashvardhan Tupe DIN 08759617 as Additional Non-Executive Director of the Company with effect from 30th March, 2026.
3. The appointment of Mr. Sandip Sharma DIN 11627247 as Additional Non-Executive Independent Director of the Company with effect from 30th March, 2026
4. Approve the date and notice of the Extraordinary General Meeting of the Company scheduled to be held on 28th April, 2026, at 12:30 PM through Video Conferencing (VC) or Other Audio Visual Means (OAVM).

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the following:

1. The appointment of Mr. Sumit Pawar as Chief Financial Officer of the Company with effect from 30th March, 2026. **(Annexure-A)**
2. The appointment of Mr. Yashvardhan Tupe DIN 08759617 as Additional Non-Executive Director of the Company with effect from 30th March, 2026. **(Annexure-A)**
3. The appointment of Mr. Sandip Sharma DIN 11627247 as Additional Non-Executive Independent Director of the Company with effect from 30th March, 2026 **(Annexure-A)**
4. Approve the date and notice of the Extraordinary General Meeting of the Company scheduled to be held on 28th April, 2026, at 12:30 PM through Video Conferencing (VC) or Other Audio Visual Means (OAVM).

This complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on your records.

Thanking you
Yours Faithfully

For Asston Pharmaceuticals Limited

Rishi Upadhaya
Digitally signed by Rishi Upadhaya
Date: 2026.03.30 16:27:09 +05'30'

Rishi Upadhaya
Company Secretary and Compliance Officer
A74324

Encl: As above

Annexure-A

The details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. **HO/49/14/14(7)2025-CFD-POD2/I/3762/2026** issued on July 11, 2023, last updated on 30th January,2026 are as follows:

S.NO.	PARTICULARS	Mr. Sumit Pawar	Mr. Yashvardhan Tupe	Mr. Sandip Sharma
1	Reason for change	Appointment	Appointment	Appointment
2	Date of appointment	30th March, 2026	30th March, 2026	30th March, 2026
3	Brief Profile	Mr. Sumit Pawar is a Commerce graduate having a rich experience of over 3 years in the field of finance & accounting management. He has an understanding of diverse business processes and strategy development. His association with the Company shall be valuable to build financial models and implement plans and strategies that promote the attainment of reasonably set company goals. His experience shall provide operational and financial efficacy to the company	Mr. Yashvardhan Tupe holds a Bachelor's degree in Mechanical Engineering (B.E. Mechanical Engineering) and a Master of Science (M.Sc.) in Management and International Business. With a strong academic background and relevant exposure, particularly aligned with the operational and strategic aspects of the manufacturing industry, the proposed appointee is expected to contribute effectively to the Company's growth, governance framework, and long-term business strategy	Mr. Sandip Sharma is a qualified Company Secretary with over two years of professional experience in corporate law, governance, and regulatory compliance. He has successfully cleared the Independent Director Examination conducted by the Indian Institute of Corporate Affairs (IICA) and has been awarded the Certificate of Independent Director. Mr. Sandip possesses sound knowledge of the Companies Act, SEBI regulations, corporate governance frameworks, and secretarial standards. During his professional tenure, he has been actively involved in ensuring statutory compliance, advising management on corporate legal matters, conducting board and committee meetings, maintaining statutory records, and

				supporting strategic decision-making processes.
4	Disclosure of relationships between/with Directors	Mr. Sumit Pawar is not related to any Director on the Board of the Company.	Mr. Yashvardhan Tupe is not related to any Director on the Board of the Company.	Mr. Sandip Sharma is not related to any Director on the Board of the Company.